Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
Miami Breast Cancer Conference
Miami Breast Cancer Conference
For 37 years, the multidisciplinary
Miami Breast Cancer Conference
has met this educational need—bringing together surgical, medical, and radiation oncologists, as well as geneticists, pathologists, radiologists, and supportive care specialists—to improve the care for patients with breast cancer.
New Combination Regimens Show Promise in Patients with Breast Cancer and Central Nervous System Metastases
Miami Breast Cancer Conference 2019
Tucatinib and neratinib show encouraging activity in patients with advanced breast cancer and central nervous system metastases.
Read More ›
Targeting Molecular Drivers in Breast Cancer Brain Metastases Could Have Therapeutic Potential
Miami Breast Cancer Conference 2019
Alterations in CDK and PI3K pathways are frequent in breast cancer brain metastases; could targeting these genetic alterations lead to improved survival?
Read More ›
New Insights into Genetics May Soon Guide Targeted Therapies for Patients with Breast Cancer and Central Nervous System Metastases
Miami Breast Cancer Conference 2019
New research reveals that brain metastases harbor distinct clinically actionable genetic alterations compared with primary tumors and extracranial metastases.
Read More ›
Analysis Reveals Need for Diarrhea Prophylaxis in Patients with HER2-Positive Breast Cancer Receiving Neratinib
Miami Breast Cancer Conference 2019
Read More ›
Trastuzumab Deruxtecan Shows “Spectacular” Efficacy in Late-Line Setting for HER2-Positive Breast Cancer
Miami Breast Cancer Conference 2019
DS-8201 yields exciting results in HER2-positive, TDM-1 resistant, or refractory metastatic disease, but providers should remain vigilant about the incidence of interstitial lung disease.
Read More ›
Tucatinib Prolongs Survival in HER2-Positive Advanced Breast Cancer, Including in Patients with CNS Metastases
Miami Breast Cancer Conference 2019
With several new therapies on the horizon for HER2-positive metastatic breast cancer, tucatinib stands out for its notable activity in patients with brain metastases.
Read More ›
Novel Therapies on the Horizon in HER2-Positive Metastatic Breast Cancer
Miami Breast Cancer Conference 2019
Treatment options continue to emerge for patients with HER2-positive advanced breast cancer, with some generating more buzz than others.
Read More ›
Does Size Matter? Determining the Size Threshold for Treating Invasive HER2-Positive Breast Cancer
Miami Breast Cancer Conference 2019
Should all patients with HER2-positive tumors between 1 cm and 2 cm receive neoadjuvant chemotherapy? Experts weigh in.
Read More ›
Does Time to Initiate Adjuvant Chemotherapy Affect Outcomes in HER2-Positive Breast Cancer?
Miami Breast Cancer Conference 2019
A study of a large national database suggests that 31 to 60 days postsurgery is ideal.
Read More ›
Neratinib Demonstrates Promising Activity in Patients with HER2-Positive Metastatic Breast Cancer and CNS Metastases
Miami Breast Cancer Conference 2019
Central nervous system objective responses were observed in patients with HER2-positive metastatic breast cancer treated with neratinib in 3 separate clinical trials.
Read More ›
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us